



FIG 1: Kinetic of conversion of Compound 40 to Compound 152



$$K_m = 37.9 \pm 5.7 \mu\text{M}; \quad k_{\text{cat}} = 0.406 \pm 0.026 \text{ min}^{-1}$$

PAT058587-WO-PCT

FIG. 2: Dose dependent *in vivo* efficacy of Compound 40 in high AKR1C3 expressing human lung cancer xenograft NCI-H1944

PAT058587-WO-PCT

FIG. 3: Dose dependent *in vivo* efficacy of Compound 40 in the KEAP1 mutant and moderately AKR1C3 expressing human lung cancer xenografts NCI-H1944 and NCI-H460

